Central Precocious Puberty Market, by Drug (Leuprolide Acetate, Triptorelin, Histrelin Acetate, and Nafarelin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Mar 2022

Code : CMI4960

Pages :167

Formats :

Excel and PDF

Industry : Pharmaceutical

Central Precocious Puberty MarketSize and Trends

The global central precocious puberty market is estimated to be valued at US$ 1,595.2 Mn in 2022 and expected to exhibit a CAGR of 7.9% over the forecast period (2022-2030).

Figure 1: Global Central Precocious Puberty Market Share (%) Analysis, By Drug, 2022

Increasing product launches and approvals for the treatment of central precocious puberty are expected to drive the market growth

Market players are focusing on obtaining product approval from regulatory authorities such as U.S. Food and Drug Administration (FDA), which is expected to augment the market growth over the forecast period. For instance, in May 2020, Tolmar Pharmaceuticals, Inc., a pharmaceutical company, received approval for its New Drug Application (NDA) from the U.S. FDA for FENSOLVI (leuprolide acetate) for injectable suspension for the treatment of pediatric patients aged two years and older with central precocious puberty.

Increasing partnerships and agreements among market players are expected to augment the market growth

Market players are focusing on various inorganic strategies such as partnerships and agreements, which is anticipated to propel the global central precocious puberty market growth over the forecast period. For instance, in January 2016, Debiopharm International SA (Debiopharm), part of Debiopharm Group, entered into an exclusive distribution agreement with Arbor Pharmaceuticals, a pharmaceutical company, for the commercialization and promotion of triptorelin 22.5 mg for CPP in the U.S.